Titration and Tolerability of Sacubitril/Valsartan for Patients With Heart Failure in Clinical Practice
暂无分享,去创建一个
F. McAlister | G. Oudit | J. Ezekowitz | M. Shanks | D. Paterson | C. Westerhout | A. Du | M. Hanninen | Jissy Thomas
[1] S. Stemkowski,et al. An Early View of Real-World Patient Response to Sacubitril/Valsartan: A Retrospective Study of Patients with Heart Failure with Reduced Ejection Fraction , 2018, Advances in Therapy.
[2] P. Martens,et al. Insights into implementation of sacubitril/valsartan into clinical practice , 2018, ESC heart failure.
[3] M. Lelonek,et al. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland. , 2018, Kardiologia polska.
[4] R. McKelvie,et al. 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. , 2017, The Canadian journal of cardiology.
[5] M. Barrett,et al. 14 The use of sacubitril/valsartan: a real world experience in a high volume specialist heart failure service , 2017, Heart.
[6] L. Dyall,et al. 13 Keeping up the beat: a quality improvement project on heart failure monitoring & management , 2017 .
[7] Emily C. O'Brien,et al. Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From Get With the Guidelines-Heart Failure (GWTG-HF). , 2017, JACC. Heart failure.
[8] F. McAlister,et al. The current and future financial burden of hospital admissions for heart failure in Canada: a cost analysis. , 2016, CMAJ open.
[9] R. Wachter,et al. Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double‐blind, randomized comparison of two uptitration regimens , 2016, European journal of heart failure.
[10] Akshay S. Desai,et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.
[11] Karl Swedberg,et al. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. , 2013, European heart journal.
[12] Paul A. Harris,et al. Procurement of shared data instruments for Research Electronic Data Capture (REDCap) , 2013, J. Biomed. Informatics.
[13] G. Fonarow,et al. Epidemiology and risk profile of heart failure , 2011, Nature Reviews Cardiology.
[14] F. McAlister. Cardiac resynchronization therapy for heart failure: a hammer in search of nails. , 2008, Circulation.
[15] R. Stafford,et al. Off-label prescribing among office-based physicians. , 2006, Archives of internal medicine.
[16] P. Armstrong,et al. The Use of -Blockers in a Tertiary Care Heart Failure Clinic , 2004 .
[17] M. Wiktorowicz,et al. Emergent Patterns in the Regulation of Pharmaceuticals: Institutions and Interests in the United States, Canada, Britain and France , 2003, Journal of health politics, policy and law.
[18] Harlan M Krumholz,et al. Representation of the elderly, women, and minorities in heart failure clinical trials. , 2002, Archives of internal medicine.